Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency

Journal of the American Society of Nephrology

Volumn 9, Issue 4, 1998, Pages 655-663

  Patruta, Sanda I ^a   Edlinger, Roland ^a   Sunder Plassmann, Gere ^a   Hörl, Walter H ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FERRITIN; HEPARIN; IRON BINDING PROTEIN; LIQUEMINE ROCHE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; ESCHERICHIA COLI; FEMALE; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; MALE; NEUTROPHIL; PHAGOCYTOSIS; PRIORITY JOURNAL; UREMIA;

EID: 0031949458     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Ali M, Rigolosi R, Fayemi AO, Braun EV, Fascino J, Singer R: Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1: 652-655, 1982
2. Schaefer RM, Schaefer L: Management of iron substitution during r-HuEPO-therapy in chronic renal failure patients. Erythropoiesis 3: 71-75, 1992
3. Sunder-Plassmann G, Hörl WH: Iron metabolism and iron substitution during erythropoietin therapy. Clin Invest 72: S11-S15, 1994
4. Nyvad O, Danielsen H, Madsen S: Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. Lancet 344: 1305-1306, 1994
5. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26: 41-46, 1995
6. Sepandy F, Jindal K, West M, Hirsch D: Economic appraisal of maintenance parenteral iron administration in treatment of anemia in chronic hemodialysis patients. Nephrol Dial Transplant 11: 319-322, 1996
7. Taylor JE, Peat N, Porter C, Morgan AG: Regular low-dose intravenous iron therapy improves response to erythropoietin in hemodialysis patients. Nephrol Dial Transplant 11: 1079-1083, 1996
8. Sunder-Plassmann G, Hörl WH: Importance of iron supply for erythro-poietin therapy. Nephrol Dial Transplant 10: 2070-2076, 1995
9. Hörl WH, Cavill I, Macdougall IC, Schaefer RM, Sunder-Plassmann G: How to diagnose and correct iron deficiency during r-HuEPO therapy: A consensus report. Nephrol Dial Transplant 11: 246-250, 1996
10. Hörl WH: How to get the best out of r-HuEPO. Nephrol Dial Transplant 10[Suppl 2]: 92-95, 1995
11. Kaufman J, Reda D, Goldfarb D, Kleinman J, Vaamonde C: Diagnosis and treatment of iron deficiency in patients on maintenance recombinant human erythropoietin (rHuEPO) [Abstract]. J Am Soc Nephrol 7: 1450, 1996
12. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end stage renal disease with recombinant human erythropoietin: Results of a combined phase I and phase II clinical trial. N Engl J Med 316: 73-78, 1987
13. Tsobanelis T, Hoppe D, Scigalla P, Grützmacher P: Optimierte Behandlung der renalen Anämie mit kombinierter intravenöser Eisen- und Ultra-low-dose-Erythropoietin-Substitution [Abstract]. Nieren-Hochdruckkr 20: 454, 1991
14. Anastassiades EG, Howarth D, Howarth J, Shankes D, Waters HM, Hyde K, Geary CG, Lin Yin JA, Gokal R: Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 8: 846-853, 1993
15. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR: Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann Intern Med 111: 992-1000, 1989
16. Eschbach JW: Turning points: Anemia. Dial Transplant 25: 725-727, 1996
17. Tielemans C, Lenclud C: Respective role of hemodialysis and desferrioxamine therapy in the risk from infection of hemodialysed patients. Q J Med 68: 573-574, 1988
18. Seifert A, von Herrath D, Schaefer K: Iron overload but not treatment with desferrioxamine favours the development of septicaemia in patients on maintenance haemodialysis. Q J Med 65: 1015-1024, 1987
19. van Asbeck BK, Marx JJM, Struyvenberg A, van Kats JH, Verhoef J: Effect of iron (III) in the presence of various ligands on the phagocytic and metabolic activity of human polymorphonuclear leukocytes. J Immunol 132: 851-856, 1984
20. Waterlot Y, Cantinieaux B, Hariga-Muller C, de MaertelaereLaurent E, Vanherweghem JL, Fondu P: Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: The critical role of iron overload. Br Med J 291: 501-504, 1985
21. Flament J, Goldman M, Waterlot Y, Dupont E, Wybran J, Vanherweghem JL: Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload. Clin Nephrol 25: 227-230, 1986
22. Boelaert JR, Cantinieaux BF, Hariga CF, Fondu PG: Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 5: 504-507, 1990
23. Bothwell TH, Charlton RW, Motulsky AG: Hemochromatosis. In: The Metabolic and Molecular Bases of Inherited Disease, edited by Scriver CR, Beaudet AL, Sly WS, Valle D, New York, McGraw-Hill, 1995, pp 2237-2269
24. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Scvhatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13: 399-408, 1995
25. Nauseef WM, Metcalf JA, Root PK: Role of myeloperoxidase in the respiratory burst of human neutrophils. Blood 61: 483-492, 1983
26. Metcalf JA, Gallin JI, Nauseef WM, Root RK: Laboratory manual neutrophil function. New York, Raven, 1986, pp 2-5
27. McCall C, Schmitt J, Cousart S, O'Flaherty J, Bass D, Wykle R: Stimulation of hexose transport by human polymorphonuclear leukocytes: A possible role for protein kinase C. Biochem Biophys Res Commun 126: 450-456, 1985
28. Moiola F: Phagocytosis, F-actin polymerization and cell volume of bovine neonatal neutrophils: A comparative study with adult cattle [Dissertation]. University of Bern, 1992
29. Alexiewicz JM, Smogorzewski M, Fadda GZ, Massry SG: Impaired phagocytosis in dialysis patients: Studies on mechanisms. Am J Nephrol 11: 102-111, 1991
30. 2 consumption by PMNL from humans and rats with CRF: Role of secondary hyperparathyroidism. Kidney Int 42: 602-609, 1992
31. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440-3450, 1985
32. Godfrey K: Comparing the means of several groups. N Engl J Med 313: 1450-1456, 1985
33. Besarab A: Optimizing epoietin therapy in end-stage renal disease: The case for subcutaneous administration. Am J Kidney Dis 22[Suppl 1]: 13-22, 1993
34. Worwood M: Serum ferritin. In: Methods Haematology, Vol. 1, edited by Cook JD, New York, Edinburgh, Churchill Livingstone, 1980, pp 58-89
35. Gokal R, Millard PR, Weatherall DJ, Callender STE, Ledingham JGG, Oliver DO: Iron metabolism in hemodialysis patients. Q J Med 48: 369-391, 1979
36. Blumberg AB, Marti HRM, Graber CG: Serum ferritin and bone marrow iron in patients undergoing continuous ambulatory peritoneal dialysis. JAMA 250: 3317-3319, 1983
37. Bell JD, Kincaid WR, Morgan RG, Bunce H, Alpergin JB, Sarles HE, Remmers AR: Serum ferritin assay and bone-marrow iron stores in patients on maintenance hemodialysis. Kidney Int 17: 237-241, 1980
38. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321: 158-163, 1989
39. Blumenkrantz MJ, Kopple JD, Gutman RA, Chan YK, Barbour GL, Roberts C, Shen FH, Gandhi VC, Tucker CT, Curtis FK, Coburn JW: Methods for assessing nutritional status of patients with renal failure. Am J Clin Nutr 33: 1567-1585, 1980
40. Hakim R, Levin N: Malnutrition in hemodialysis patients. Am J Kidney Dis 21: 125-137, 1993
41. Milman N: Plasma transferrin and the relation to iron status in patients with chronic uremia. Clin Nephrol 16: 314-320, 1981
42. Miller DG, Levine S, Bistrian B, D'Elia JA: Diagnosis of protein calorie malnutrition in diabetic patients on hemodialysis and peritoneal dialysis. Nephron 33: 127-132, 1983
43. Iida T, Umezawa K, Tanaka K, Koga Y, Nakazawa, Satoh T: Polymorphonuclear cells in chronic hemodialysis patients have intact phagocytotic and impaired bactericidal activities. Nephron 75: 41-47, 1997
44. Hirabayashi Y, Kobayashi T, Nishikawa A, Okazaki H, Aoki T, Takaya J: Oxidative metabolism and phagocytosis of polymorphonuclear leukocytes in patients with chronic renal failure. Nephron 49: 305-312, 1988
45. Vanholder R, Ringoir S: Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review. J Am Soc Nephrol 3: 1541-1554, 1993
46. Vanholder R, van Biesen W, Ringoir S: Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney Int 44: 208-214, 1993
47. Vanholder R, De Smet R, Jacobs V, Van Landschoot N, Waterloos MA, Vogeleere P, Ringoir S: Uraemic toxic retention solutes depress polymorphonuclear response to phagocytosis. Nephrol Dial Transplant 9: 1271-1278, 1994
48. Ward RA, McLeish KR: Polymorphonuclear leukocyte oxidativeburst is enhanced in patients with chronic renal insufficiency. J Am Soc Nephrol 5: 1697-1702, 1995
49. 3 or calcium channel blocker. Am J Nephrol 13: 467-472, 1993
50. i and carbohydrate metabolism of PMNL of dialysis patients. Kidney Int 47: 1741-1745, 1995
51. Drüeke TB, Bárány P, Cazzola M, Eschbach W, Grützmacher P, Kaltwasser JP, Macdougall IC, Pippard MJ, Shaldon S, Van Wyck D: Management of iron deficiency in renal anemia: Guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 48: 1-8, 1997